Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,739,420
  • Shares Outstanding, K 77,692
  • Annual Sales, $ 10,680 K
  • Annual Income, $ -98,150 K
  • 60-Month Beta 1.78
  • Price/Sales 264.43
  • Price/Cash Flow N/A
  • Price/Book 12.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 9
  • High Estimate 0.22
  • Low Estimate -0.46
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.30 +20.34%
on 06/12/20
38.52 -8.46%
on 07/07/20
+2.27 (+6.88%)
since 06/10/20
3-Month
25.60 +37.73%
on 05/13/20
38.52 -8.46%
on 07/07/20
+8.03 (+29.49%)
since 04/09/20
52-Week
12.59 +180.06%
on 11/06/19
38.52 -8.46%
on 07/07/20
+14.76 (+72.00%)
since 07/10/19

Most Recent Stories

More News
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod

Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.

JNJ : 142.37 (-0.08%)
GILD : 76.32 (+2.16%)
BMY : 57.43 (-1.17%)
FATE : 35.26 (-3.00%)
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus

FATE : 35.26 (-3.00%)
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

FATE : 35.26 (-3.00%)
Fate Therapeutics Announces Pricing of Public Offering of Common Stock

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

FATE : 35.26 (-3.00%)
Fate Therapeutics Announces Proposed Public Offering of Common Stock

Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...

FATE : 35.26 (-3.00%)
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma

FATE : 35.26 (-3.00%)
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

FATE : 35.26 (-3.00%)
Fate Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $33.5 million in its first quarter.

FATE : 35.26 (-3.00%)
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates

FATE : 35.26 (-3.00%)
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FATE : 35.26 (-3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FATE with:

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

2nd Resistance Point 37.26
1st Resistance Point 36.26
Last Price 35.26
1st Support Level 34.70
2nd Support Level 34.14

See More

52-Week High 38.52
Last Price 35.26
Fibonacci 61.8% 28.61
Fibonacci 50% 25.56
Fibonacci 38.2% 22.50
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar